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Abstract
Background: Alterations in serum CXCR3 ligand levels were examined in interstitial cystitis (IC)
patients; similar expression patterns in serum as well as CXCR3, CXCR3 ligands, and cytokines
expressed by peripheral and local leukocyte subpopulations were characterized during
cyclophosphamide (CYP)-induced acute cystitis in mice.
Results: Serum levels of monokine-induced by interferon-γ (IFN-γ) (MIG/CXCL9), IFN-γ-inducible
protein-10 (IP-10/CXCL10), and IFN-γ-inducible T cell α chemoattractant (I-TAC/CXCL11) were
elevated in patients with IC. These clinical features closely correlated with CYP-induced cystitis in
mice. Serum levels of these CXCR3 ligands and local T helper type 1 (Th1) cytokines were also
increased. We demonstrate that CXCR3 as well as CXCL9, CXCL10 and CXCL11 mRNA were
significantly expressed by urinary bladder lymphocytes, while CXCR3 and CXCL9 transcripts were
significantly expressed by iliac lymph node leukocytes following CYP treatment. We also show that
the number of CD4+ T cells, mast cells, natural killer (NK) cells, and NKT cells were increased at
systemic (spleen) and mucosal (urinary bladder and iliac lymph nodes) sites, following CYP-induced
cystitis in mice. Importantly, CXCL10 blockade attenuated these increases caused by CYP.
Conclusion: Antibody (Ab)-mediated inhibition of the most abundant serum CXCR3 ligand,
CXCL10, in mice decreased the local production of CXCR3 ligands as well as Th1 cytokines
expressed by local leukocytes, and lowered corresponding serum levels to reduce the severity of
CYP-induced cystitis. The present study is among the first to demonstrate some of the cellular and
molecular mechanisms of chemokines in cystitis and may represent new drug target for this disease.
Background
IC is a complex disease with symptoms including chronic
urinary bladder inflammation, characterized by increased
urinary frequency, urgency as well as suprapubic, bladder,
and pelvic pain. Estimates indicate there are ~1 million IC
cases in the United States annually, with 90% of sufferers
Published: 28 October 2008
Journal of Immune Based Therapies and Vaccines 2008, 6:6 doi:10.1186/1476-8518-6-6
Received: 9 July 2008
Accepted: 28 October 2008
This article is available from: http://www.jibtherapies.com/content/6/1/6
© 2008 Sakthivel et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 14
(page number not for citation purposes)
Journal of Immune Based Therapies and Vaccines 2008, 6:6 http://www.jibtherapies.com/content/6/1/6being women [1-3]. While the precise etiology of IC is not
known, a number of causes have been suggested, which
include: infection, autoimmunity, urinary toxins, urinary
bladder wall epithelial permeability and neurogenic
inflammation [4,5]. In several reports, CYP-induced cysti-
tis has been used as a model for IC, because these two con-
ditions share some unique aspects. Both IC and CYP-
induced cystitis are non-infectious, cause urinary bladder
inflammation, and disrupt the urothelium as well as elec-
trochemical, neurochemical, and micturition reflex ele-
ments [6-11]. Indeed, cystitis produced by the
administration of CYP is a result of renal excretion of
hepatic metabolites, particularly acrolein that contributes
to hemorrhagic cystitis and induction of prostaglandins
via cyclooxygenase-2 and nitric oxide for the stimulation
of cholinergic and inflammatory responses [12-15].
Chemokines have emerged as major factors in inflamma-
tory diseases. These chemotactic cytokines are also consid-
ered neuromodulatory agents [16,17]. Further
characterization is necessary to better delineate the molec-
ular and cellular inflammatory mechanisms of CYP-
induced cystitis. Recently, CX3CR1 and CX3CL1 expres-
sion by cells of the urinary bladder have been shown to be
enhanced following CYP-induced cystitis [18]. Other
chemokines may also be involved in the pathology of cys-
titis. For example, CXCL9, CXCL10, and CXCL11 bind to
a common receptor, CXCR3. These chemokines stimulate
and attract CXCR3+ monocytes/macrophages, T cells, NK
cells, mast cells and dendritic cells. Many of these leuko-
cytes have been suggested to have a role in cystitis. To this
end, CXCR3 expression and CXCL10-signaling by sensory
neurons correlate with the maintenance phase of persist-
ent pain [19]. CXCL10 expression has also been shown to
be elevated in bladders following cancer therapy and
febrile urinary infection [20,21].
While there are no mouse models that precisely replicate
either the classical or non-ulcerative forms of IC, the CYP-
induced cystitis model used in this study shares many fea-
tures of the human (non-ulcerative) disease including:
urinary bladder inflammation, mastocyte infiltration, and
urothelium disruption. This study correlates IC patient
serum CXCR3 ligand levels with those of disease free
donors as well as with serum from mice with CYP-induced
cystitis. Serum CXCL9, CXCL10, and CXCL11 levels of
CYP-treated mice given control Ab were compared to sim-
ilar mice that received anti-CXCL10 Ab. Urinary bladder
histology as well as mucosal (iliac lymph node and uri-
nary bladder) and peripheral (spleen) leukocyte expres-
sion of CXCR3, CXCL9, CXCL10, and CXCL11 mRNA
transcripts as well as CD4+ T cell, mast cell, and NK/NKT
cell numbers were compared among naïve and CYP-
treated mice given control or anti-CXCL10 Abs. We show
that serum levels of CXCL9, CXCL10, and CXCL11 were
increased in IC patients. These clinical trends were consist-
ent with CYP-induced cystitis in mice; CXCR3 ligands
were elevated in mouse serum as well as urinary bladder
and iliac lymph node lymphocytes. Importantly, cystitis
severity was reduced when anti-CXCL10 Ab was adminis-
tered during the development of CYP-induced (acute) cys-
titis in mice. This study is among the first to suggest that
modulation of chemokine interactions can affect the out-
come of CYP-induced cystitis.
Methods
Patients
A total of 48 age-matched serum samples were collected
by Clinomics Biosciences, Inc. (now Cytomyx Holdings,
PLC) from a cohort of 32 untreated female patients with
chronic and relapsing IC with a mean age of 41.6 years
ranging from 31 to 76. In addition, 16 serum samples
from unaffected, healthy female donors with a mean age
of 47 years ranging from 38 to 62 were collected. Healthy
donors had no active urologic disease or symptoms at the
time of blood collection. The diagnosis of IC was based
strictly on the criteria set forth by the National Institute of
Diabetes, Digestive, and Kidney Disease [22]. No subject
had a urinary tract infection, hydro-distension, or any
intravescical treatment for at least 12 weeks prior to blood
collection. All subjects gave written informed consent and
were approved by the Clinomics Biosciences Research
Ethics Committee (Pittsfield, MA, USA). Subsequently,
the University of Louisville Institutional Review Board
(IRB) approved the use of these diagnostic specimens in
accordance with the Department of Health and Human
Service Policy for the Protection of Human Research Sub-
jects 45 CFR 46.101(b) 2 and use of archived de-identified
materials.
Animals
Female BALB/c mice aged 8 to 12 weeks were purchased
from Jackson Laboratories (Bar Harbor, ME). Female New
Zealand rabbits aged 4 to 5 months (Myrtle's Rabbitory;
Thompson Station, TN) were used to generate anti-
CXCL10 Abs. Animals were housed and maintained
under specific pathogen-free housing. Experimental
groups consisted of five mice and each study was repeated
three times.
Anti-CXCL10 Ab generation and treatment
Recombinant mouse CXCL10 was purchased from Pepro-
Tech (Rocky Hill, NJ). The endotoxin level of this chem-
okine was quantified to be < 5 EU/mg by the chromogenic
Limulus amebocyte lysate assay (Cape Cod, Inc. Falmouth,
MS). CXCL10 plus complete Freund's or incomplete Fre-
und's adjuvants (Sigma, St. Louis, MO) were used to gen-
erate anti-CXCL10 Ab titers of ~1:2 × 106. Pre-immune or
anti-CXCL10 Ab was purified using an IgG isotype-spe-
cific protein A column (Pierce Biotechnology, Rockford,Page 2 of 14
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enzyme-linked immunosorbent assay (ELISA). No cross-
reactivity was detected when tested against other chemok-
ines (CXCL8, CXCL9, CXCL11, CXCL12, CXCL13, CCL2,
CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, and XCL1) or
cytokines (IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, and TNF-α)
(PeproTech, Rocky Hill, NJ). Anti-CXCL10 Ab titers (or
control Ab) were adjusted to 1:4 × 105 (i.e., 50 times dilu-
tion) in phosphate-buffered saline (PBS) and subse-
quently used as "Ab solutions" for treatment.
CYP-induced cystitis and Ab treatment
CYP administered every 3 days for 10 days can lead to
chronic cystitis [23]. In this study, a single intraperitoneal
injection of CYP was administered to elicit acute cystitis
within 5 days [18]. CYP was obtained from ICN Biomed-
icals, Inc. (Aurora, OH). Mice of positive control Ab- and
anti-CXCL10 Ab-treated groups received intraperitoneal
injections of CYP (300 mg/kg) in 200 μl of PBS to induce
cystitis. Acute cystitis was studied during the initial 5 days
following CYP treatment. 24 hrs before treatment with
CYP and every 48 hrs thereafter, mice received 200 μl
intraperitoneal injections of either anti-CXCL10 or con-
trol Ab solutions. The negative control groups (without
CYP treatment) also received anti-CXCL10 or control Ab
solutions.
CXCL9, CXCL10 and CXCL11 ELISAs
Serum concentrations of human and mouse CXCL9,
CXCL10, and CXCL11 were determined by ELISA (R&D
Systems, Minneapolis, MN), according to the manufac-
turer's instructions. Each sample was analyzed in triplicate
and compared with a standard curve using ELISA tech-
niques to measure CXCL9, CXCL10, and CXCL11 concen-
trations. In brief, samples and standards were added to the
wells and incubated for 2 hrs at room temperature (RT).
Next, conjugate-detection solutions were added to each
well, and the plates were further incubated for 2 hrs at RT.
Then, substrate solution was added to each well and plates
were incubated for 30 minutes. Finally, the stop solution
was added to each well and the reaction was read at an
optical density of 450 nm after 30 minutes using a λ cor-
rection of 540 and 570 nm. ELISA assays were capable of
detecting > 10 pg/ml of each chemokine.
RNA isolation and gene expression analysis
RNA was isolated from spleen, iliac lymph node, and uri-
nary bladder leukocytes from CYP-induced and unaf-
fected mice, using Tri-reagent™ (Molecular Research
Center, Cincinnati, OH), according to the manufacturer's
protocols. Potential genomic DNA contamination was
removed from these samples by treating them with
RNase-free DNase (Invitrogen, San Diego, CA) for 15
mins at 37°C. RNA was precipitated and resuspended in
RNA Secure™ (Ambion, Austin, TX) and cDNA was gener-
ated by reverse transcribing approximately 1.5 μg of total
RNA using Taqman™ reverse transcription reagent
(Applied Biosystems, Foster City, CA), according to the
manufacturer's protocols. Mouse mRNA sequences of
CXCL9, CXCL10, CXCL11, CXCR3, IFN-γ, IL-12p40, TNF-
α, and 18S rRNA were obtained from the NIH-National
Center for Biotechnology Information (NCBI) gene bank
database accession numbers M33266, NM_008599,
NM_019494, AF045146, NM_008337, M86671,
NM_013693, and X00686.1. These sequences were used
to design primers for real-time polymerase chain reaction
(RT-PCR) analysis, which generated amplicons of 100, 95,
93, 96, 98, 97, 102, and 149 base-pair fragments of
CXCL9, CXCL10, CXCL11, TNF-α, IFN-γ, IL-12p40 and
CXCR3 mRNAs, and 18S rRNA, respectively.
Primers were designed using the Primer 3 software pro-
gram from Whitehead Institute at the Massachusetts Insti-
tute of Technology (MIT) (Boston, MA). Thermodynamic
analysis of the primers was conducted using the following
computer programs: Primer Premier™ (Integrated DNA
Technologies, Coralville, Iowa) and MIT Primer III (Bos-
ton, MA). The resulting primer sets were compared against
the entire murine genome to confirm specificity and
ensure that the primers flanked mRNA splicing regions.
cDNA was generated, as before, and amplified with spe-
cific cDNA primers using SYBR® Green PCR master mix
reagents (Applied Biosystems). Numbers of mRNA copies
(> 10) relative to 18S rRNA copies were evaluated by RT-
PCR analysis using the Bio-Rad Icycler and software (Her-
cules, CA).
Histological evaluation
Five days after CYP (or vehicle alone) administration,
mice were sacrificed and urinary bladders were fixed, sec-
tioned at 6 μm, and stained with hematoxylin and eosin.
The sections were microscopically examined at magnifica-
tions of 40× and 100× and scored for the severity of cysti-
tis. The data presented are the mean of the number and
percentage of changes ± SD of these experiments. Urinary
bladders were preserved using 10% neutral formalin fixa-
tive for 24 hrs and embedded in paraffin. Fixed tissues
were sectioned at 6 μm, stained with hematoxylin and
eosin, and examined by light microscopy. The inflamma-
tory state of each urinary bladder was characterized and
scored as follows: having no change when compared with
tissue samples from untreated mice (score = 0); having a
few multi-focal mononuclear cell infiltrates (score = 1);
having minimal hyperplasia with a mixture of mononu-
clear and multi-nucleated cells (score = 2); having major
hyperplasia (score = 3) or having major hyperplasia and
epithelial erosions with inflammation in the sub-mucosa
(score = 4).Page 3 of 14
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Single-cell suspensions of spleens and iliac lymph nodes
from each mouse were passed through a sterile wire screen
(Sigma). Cell suspensions were washed twice in RPMI
1640. For the isolation of leukocytes from urinary blad-
ders, this tissue was cut into small fragments and incu-
bated for 1 hour at 37°C in RPMI 1640 containing 0.8 g/
ml of collagenase II. The cell pellet was washed with
medium, filtered, washed and resuspended in Hank's
buffered salt solution. The cell suspension was further
purified using a discontinuous Percoll (Pharmacia, Upp-
sala, Sweden) gradient and collected at the 40% to 75%
interface. Lymphocytes were maintained in complete
medium, which consisted of RPMI 1640 supplemented
with 10 ml/L of nonessential amino acids (Mediatech,
Washington, DC), 1 mM sodium pyruvate (Sigma), 10
mM HEPES (Mediatech), 100 U/ml penicillin, 100 μg/ml
streptomycin, 40 μg/ml gentamycin (Elkins-Sinn, Inc.,
Cherry Hill, NJ), 50 μM mercaptoethanol (Sigma), and
10% fetal bovine serum (FBS) (Sigma). The cells were
stained with phycoerythrin chychrome-5 (PE-CY-5)-con-
jugated anti-CD4 (H129.19), allophycocyanin (APC)-
conjugated anti-LY6G (RB6-8C5), PE-conjugated anti-
CD8 (LY-2 53-6.7), -CD19 (1D3), -CD11c or -DX-5
(DX5), APC-conjugated rat anti-mouse CD117, APC-con-
jugated anti-mouse CD34, and fluorescein isothiocynate
(FITC)-conjugated anti-CD3 (145-2C11) or CD11b (M1/
70) Abs (BD-PharMingen San Diego CA) for 30 mins with
shaking. Lymphocytes were then washed with FACS
buffer (PBS with 1% BSA) and fixed in 2% paraformalde-
hyde (Sigma) in PBS and analyzed by flow cytometry
(Becton Dickinson, San Diego, CA).
Statistical analysis
The traditional α-value, i.e., p < 0.01, was used to evaluate
the statistical significance of this study. The power of these
studies was carried out to determine the probability (1 –
β) of detecting a significant difference (δ) between control
and experimental or unaffected groups or samples. The
data are expressed as the mean ± SD and compared using
a two-tailed paired student's t-test or an unpaired Mann
Whitney U-test. The results were analyzed using Microsoft
Excel (Microsoft, Seattle, WA) for Macintosh computers.
Single-factor and two-factor variance ANOVA analyses
were used to evaluate groups and subgroups, respectively.
Kolmogorov-Smirnov (K-S) two-sample test using CELL
Quest Software (BD-PharMingen) for Macintosh comput-
ers was used to compute the statistical significance
between histograms.
Results
Serum CXCL9, CXCL10, and CXCL11 expression during IC
The serum levels of CXCL9 and CXCL10 in IC patients
were significantly higher than levels in unaffected healthy
donors. In particular, the difference in serum levels
between IC patients and healthy donors were greatest for
CXCL9 (p < 0.001), followed by CXCL10 (p < 0.01) and
CXCL11 (p > 0.1) (Figure 1A). These CXCR3 ligand levels
also correlated (although not statistically significant) with
disease severity as manifested by pathological reports for
each individual patient (data not shown). These patients
showed multiple pathological features of tissue damage
that frequently included urothelium denudation, mucosal
edema, and/or leukocyte infiltration.
Serum CXCL9, CXCL10, and CXCL11 levels in mice after 
CYP induction
CYP-induced cystitis in mice led to substantial increases in
serum levels of CXCL10 >> CXCL9 when compared with
the levels in unaffected controls (Figure 1B). In confirma-
tion with serum CXCR3 ligand levels in IC patients,
murine CXCL11 levels did not significantly change in
groups induced with CYP. In summary, mice with CYP-
induced cystitis expressed higher serum CXCL10 > CXCL9
than unaffected controls, while IC patients displayed
higher CXCL9 > CXCL10 serum levels than unaffected
individuals.
CXCL10 blockade effects on cystitis severity
Due to the high levels of CXCL10 observed during CYP-
induced cystitis, we next treated mice with control or anti-
CXCL10 Abs to determine if inhibition of this chemokine
would modulate disease. Unaffected mice treated with
either control or anti-CXCL10 Abs showed no significant
change in serum CXCR3 ligand levels. However, increases
in serum CXCL10 (and CXCL9) concentrations were sig-
nificantly reduced following CXCL10 blockade in mice
that received CYP. Despite the reduction of serum CXCL9
and CXCL10 levels following anti-CXCL10 Ab treat-
ment(s) of mice given CYP, it remained uncertain whether
CXCL10 blockade would improve the pathology of cysti-
tis. Control Ab-treated mice given CYP showed patholog-
ical signs of cystitis (i.e., urinary bladder inflammation,
discontinuous uroepitheium). Similarly, affected mice
treated with anti-CXCL10 Ab displayed a reduction in cys-
titis, as noted by a decrease in urinary bladder leukocyte
infiltrates (Figure 2). Histological differences between
control Ab- and anti-CXCL10 Ab-treated mice with CYP-
induced cystitis were scored and considered significant
when p < 0.01. In short, CXCL10 blockade significantly
reduced CYP-induced cystitis (Table 1).
CXCL9, CXCL10, CXCL11, and CXCR3 mRNA expression
CYP-induced cystitis in mice led to substantial increases in
the expression of CXCL10, CXCL11, and CXCR3 mRNA
by urinary bladder leukocytes as well as modest increases
in the expression of CXCL9 and CXCR3 transcripts by iliac
lymph node lymphocytes than compared to normal,
untreated mice (Figure 3A). In contrast, the expression of
these IFN-γ – and nuclear factor kappa B (NFκB)-induci-Page 4 of 14
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Serum CXCL9, CXCL10 and CXCL11 concentration in the IC patientsFig re 1
Serum CXCL9, CXCL10 and CXCL11 concentration in the IC patients. Panel A: Sera from IC patients (n = 32) and 
normal, healthy donors (n = 16) were isolated and evaluated for the presence of CXCR3 ligands by ELISA, capable of detecting 
>10 pg/ml of each CXCR3 ligand. The data presented are the mean CXCL9, CXCL10, and CXCL11 of IC patient and normal 
healthy donors concentrations ± SEM. Asterisks () indicate statistically significant differences, i.e., p < 0.01, between the healthy 
donors and IC patients. Panel B: Control or anti-CXCL10 Ab solutions were administered 2 days prior to CYP challenge and 
every 2 days thereafter. Five days after CYP administration, the serum levels of CXCL9, CXCL10, and CXCL11 were deter-
mined by ELISA. The data presented are the mean concentrations ± SEM in each group. Asterisks () indicate statistically signif-
icant (p < 0.01) differences between unaffected and CYP-induced groups. Triangles (▲) indicate statistically significant (p < 
0.01) differences between control Ab- and anti-CXCL10 Ab-treated groups administered CYP.
Journal of Immune Based Therapies and Vaccines 2008, 6:6 http://www.jibtherapies.com/content/6/1/6ble chemokines and CXCR3 mRNAs were significantly
diminished in splenocytes from CYP-treated mice than
compared to similar cells from control mice. Anti-
CXCL10 Ab treatment significantly decreased the expres-
sion of CXCL9 and CXCR3 mRNAs by iliac lymph node
leukocytes and reduced the production of CXCL9,
CXCL10, CXCL11, and CXCR3 mRNAs by urinary bladder
leukocytes. However, this treatment increased the expres-
sion of these transcripts by splenocytes from CYP-induced
mice than compared to controls.
IFN-γ, IL-12 p40, and TNF-α mRNA expression
To investigate local and peripheral changes in Th1 and
inflammatory cytokine expression during CYP-induced
cystitis, the levels of IFN-γ, IL-12p40, and TNF-α mRNAs
expressed by leukocytes isolated from the spleen, iliac
lymph nodes and urinary bladder were measured by
quantitative RT-PCR analysis. CYP-induced mice receiving
control Ab exhibited substantial decreases in the expres-
sion of IFN-γ, IL-12p40, and TNF-α mRNAs by spleno-
cytes; however, this treatment significantly increased the
expression of cytokines by urinary bladder leukocytes
than compared to unaffected mice (Figure 3B). Mice with
CYP-induced cystitis exhibited increased IFN-γ mRNA
Histological changes after CYP-induced cystitisFigure 2
Histological changes after CYP-induced cystitis. Control or anti-mouse CXCL10 Ab solutions were administered 2 days 
prior to CYP treatment and every 2 days thereafter. Five days after CYP administration, the urinary bladders of the mice were 
fixed, sectioned at 6 μm, and stained with hematoxylin and eosin. The sections were examined microscopically at magnification 
views of 10× and 100×. Panels A and C show the magnified sections from control Ab-treated mice while Panels B and D display 
similar sections from anti-CXCL10 Ab-treated mice given CYP to illustrate inflamed bladders and characterized differences in 
mucosal wall thickness, enlargement of mucosal layer, leukocyte infiltration, and glandular elongation.Page 6 of 14
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similar cells from unaffected mice. However, the expres-
sion of IFN-γ, IL-12p40, and TNF-α mRNAs by urinary
bladder lymphocytes from mice with cystitis were signifi-
cantly decreased following anti-CXCL10 Ab treatment
than compared to similar cells from CYP-induced mice
treated with control Ab.
Table 1: Histological evaluation of CYP-induced cystitis
Treatment/Group Number of Mice Cystitis Disease Score (0 – 4)
Control Ab-treated/Naïve 15 0
Anti-CXCL10 Ab-treated/Naïve 15 0
Control Ab treated/CYP-induced 15 3.7 ± 0.4*
Anti-CXCL10 Ab-treated/CYP-induced cystitis 15 1.6 ± 0.6*,§
The change in urinary bladder inflammation (i.e., cystitis disease score) was evaluated by histopathology. Control or anti-mouse CXCL10 Ab 
solutions were administered beginning at 2 days prior to CYP (or vehicle alone) treatment and every 2 days thereafter. Five days after CYP (or 
vehicle alone) administration, mice were sacrificed and urinary bladders were fixed, sectioned at 6 μm, and stained with hematoxylin and eosin. The 
sections were examined microscopically (at 40× magnification) and scored for the severity of cystitis. The studies were repeated three times, and 
the data presented are the mean of the cystitis disease score ± standard deviation. Differences between CYP-induced groups and unaffected groups 
were considered significant when p < 0.01 (*). Differences between control and anti-CXCL10 Ab-treated mice with CYP-induced cystitis were 
considered significant when p < 0.01 (§).
CXCR3, CXCL9, CXCL10, and CXCL11 mRNAs expression by CYP-treated miceFigure 3
CXCR3, CXCL9, CXCL10, and CXCL11 mRNAs expression by CYP-treated mice. Control or anti-mouse 
CXCL10 Ab solutions were administered 2 days prior to CYP treatment and every 2 days thereafter. Five days after CYP 
administration, total RNA was isolated from the spleen, iliac lymph nodes, or urinary bladder of the mice. Panel A: RT-PCR 
analysis of CXCR3, CXCL9, CXCL10, or CXCL11 mRNA expression was performed. Panel B: RT- PCR analysis of IFN-γ, IL-12 
p40, or TNF-α mRNA expression was performed. Log10 copies of transcripts ± SEM are expressed relative to actual copies of 
18S rRNA. Asterisks () indicate statistically significant (p < 0.01) differences between unaffected and CYP-induced groups. Tri-
angles (▲) indicate statistically significant (p < 0.01) differences between control Ab- and anti-CXCL10 Ab-treated groups 
administered CYP.Page 7 of 14
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In general, the distribution of CD3+CD8+, DX-5+, and
CD11b+ lymphocytes changed little after CYP-induced
cystitis. However, significant changes of CD4+ T cells were
noted in urinary bladders, iliac lymph nodes, and spleens
relative to unaffected mice (control or anti-CXCL10 Ab-
treated) (Figure 4 and Table 2). After the induction of cys-
titis with CYP, the percentage of CD4+ T cells decreased
from 21.6% to 2.4% of the total leukocyte population in
the spleen. Following anti-CXCL10 Ab treatment, the per-
centage of CD4+ T cells (i.e., 56.6%) in total splenocytes
was significantly higher. CYP treatment also lead to a
decrease in the percentage of CD4+ T cells from 39.3% to
3.9% in control Ab-treated mice; following anti-CXCL10
Ab treatment of CYP-challenged mice, the percentage of
CD4+ T cells in iliac lymph nodes increased to 63% of
total lymphocytes isolated from this lymphoid tissue.
CD4+ T cells comprised 4.2% of the lymphocytes taken
from the urinary bladder of unaffected mice. However,
CYP treatment significantly increased the percentage of
urinary bladder CD4+ T cells to 50.5%, but CXCL10 block-
ade of CYP-treated mice decreased this percentage to
34.2%.
Analysis of the change in the total number of CD4+ T cells
in the spleen, iliac lymph nodes, and urinary bladder told
a similar story. The total number of splenic CD4+ T cells
from CYP-induced mice decreased following CXCL10
blockade. Indeed, the effects of anti-CXCL10 Ab treatment
were most evident when comparing the change in the
number of CD4+ T cells from control Ab versus anti-
CXCL10 Ab treatment in the iliac lymph nodes (0.1 × 105
versus 1.1 × 105) and spleen (0.6 × 106 versus 5.2 × 105).
Considered together, these findings show CYP-induced
cystitis is associated with considerable reduction in the
percentage of T helper lymphocytes in the spleen and iliac
lymph nodes, but an increase in both the percentage and
the number of CD4+ T cells in the urinary bladder. Most
importantly, our data show CXCL10 blockade partially
attenuates these changes.
Mast cell changes during cystitis
Mast cells have been suggested to play a role in a subset of
IC cases. So, we next examined the changes in mast cells
during CYP-induced cystitis. Normal mice treated with
control or anti-CXCL10 Abs did not show significant
changes in the percentage of mast cells taken from the
spleen, urinary bladder, and iliac lymph nodes (Figure 4).
Change in CD4+ T and mast cells during acute cystitisFigur 4
Change in CD4+ T and mast cells during acute cystitis. Control or anti-mouse CXCL10 Ab solutions were adminis-
tered 2 days prior to CYP treatment and every 2 days thereafter. Five days after CYP administration, lymphocytes from the 
spleen, iliac lymph nodes, and urinary bladder were isolated and stained for flow cytometry analysis. Representative histograms 
are shown with the mean percentage (and total number) of spleen, iliac lymph node, and urinary bladder CD4+ T cells (Panel A), 
CD34+ cKit+cell (Panel B).Page 8 of 14
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lymph nodes, and urinary bladder after CYP induction
than compared to control animals. However, these popu-
lations were significantly reduced after anti-CXCL10 Ab
treatment.
While NK cell subsets have not been attributed to either
CYP-induced cystitis or IC, analysis of these leukocytes
revealed the number and percentage of NK and NKT cells
were elevated during CYP-induced cystitis than compared
to normal control mice (Figure 5). CXCL10 blockade
reduced the number of splenic, iliac lymph node, and uri-
nary bladder NKT cells after CYP induction as compared
to CYP-induced and control Ab treated mice. Splenic NK
cells were unchanged during cystitis, but CXCL10 block-
ade dramatically reduced the number of splenic and iliac
lymph node NK cells that were increased during this dis-
ease. Together, these results indicate that CXCL10 block-
ade modulates the number of systemic and mucosal NK
cell subsets that are altered during CYP-induced cystitis.
Discussion
At least two variants of IC have been previously described
[24-26]: classical IC and non-ulcerative IC. Patients with
non-ulcerative IC have relatively unaltered mucosa with
sparse inflammation, multiple small mucosal ruptures,
and suburothelial hemorrhages. In general, non-ulcera-
tive IC patients show a disruption of the urothelium, vas-
cular damage and mucosal mastocyte infiltration [27].
The four major pathology metrics of classical IC severity
are mast cell count, granulation tissue, vascular density in
the lamina propria and complete loss of urothelium [27-
29]. However, the contribution of T helper cells as well as
cytokines and chemokines in IC development remains
uncertain.
While there are no mouse models that precisely mimic IC,
the CYP-induced cystitis mouse model used in this study
share some features of the human disease including: uri-
nary bladder inflammation, mastocyte infiltration, and
urothelium disruption. Perhaps in association with the
differences between the various forms of IC and murine
CYP-induced cystitis, CXCL10 (followed by CXCL9) was
higher in mice with CYP-induced cystitis, but CXCL9 (fol-
lowed by CXCL10) was found to be higher in IC patients.
There is no clear explanation for these differences, espe-
cially considering the high identity and homology
between human and mouse mature CXCL9 (75% and
89%, respectively) as well as CXCL10 (71% and 82%,
respectively) proteins. However, the human cxcl9 pro-
moter has six IFN-γ response elements (γ-IRE), while the
mouse cxcl9 promoter has three. Interestingly, the mouse
cxcl10 promoter has seven γ-IRE, but human CXCL10
only has three. Taken together, the higher expression of
CXCL9 in man and CXCL10 in mouse, during clinical and
experimental disease, respectively, could be explained by
these promoter differences or the imperfect correlation
between clinical disease and the experimental mouse
model used in this study. Further studies will be required
to precisely dissect the molecular mechanisms behind
these differences.
CD4+ T cell infiltration and expression of CXCL10 is seen
in many mucosal inflammatory diseases [30-43]. In the
current study, we show for the first time that serum levels
of CXCR3 ligands are elevated in IC patients compared
with normal, healthy donors. We also demonstrate for the
first time that anti-CXCL10 Ab treatment prevents the
development and onset of CYP-induced cystitis. The abil-
ity of CXCL10 blockade to modulate local chemokines as
well as Th1 cytokine mRNA expression and to facilitate
the decline of serum levels of CXCL9 and CXCL10 is an
indication of reduced local as well as systemic inflamma-
tion. This study supports the previous finding that there
are elevated numbers of mucosal T cells during IC patho-
genesis [44].
Table 2: Changes in the number and percentage of CD4+ T cell lymphocytes.
Total CD4+ T cell Group Spleen Iliac lymph nodes Urinary bladder
Counts Control Ab-treated 24.2 × 106 ± 3.9 11.0 × 105 ± 0.9 1.49 × 104 ± 0.04
Anti-CXCL10 Ab-treated 22.0 × 106 ± 3.1 16.4 × 105 ± 1.7 2.32 × 104 ± 0.2
CYP- and control Ab-treated 0.6 × 106 ± 0.06* 0.1 × 105 ± 0.02 36.8 × 104 ± 4.6*
CYP- and anti-CXCL10 Ab-treated 5.2 × 106 ± 0.6 1.1 × 105 ± 0.1* 22.9 × 104 ± 3.3*
Percentage Control Ab-treated 21.6 ± 1.3 39.3 ± 4.4 4.24 ± 0.23
Anti-CXCL10 Ab-treated 20.8 ± 3.8 30.9 ± 3.2 16.3 ± 2.1*
CYP- and control Ab-treated 2.4 ± 1.9 3.9 ± 0.19 50.5 ± 7.1
CYP- and anti-CXCL10 Ab-treated 56.6 ± 6.5* 63.0 ± 7.2* 34.2 ± 3.7*
Control or anti-mouse CXCL10 Abs solutions were administered beginning 2 days prior to CYP treatment and every 2 days thereafter. Five days 
after CYP administration, lymphocytes from the spleen, iliac lymph nodes, and urinary bladder were isolated, stained for CD3 and CD4 expression, 
and analyzed by flow cytometry. The studies were repeated three times, and the data presented are the mean of the number or percent change ± 
SEM (n = 10). Differences between experimental groups were considered significant when p < 0.01 (*).Page 9 of 14
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the percentage of CD4+ T cells in the spleen of naïve mice,
but inhibition of CXCL10 in CYP-treated mice with cysti-
tis lead to an increase in the percentage of T helper splen-
ocytes. We believe these findings are a result of numerous
interactions including the ability of CYP to selectively
inhibit the proliferation of T regulatory (Treg) cells with-
out affecting Th1 cells that are typically CXCR3+. The pres-
ence of anti-CXCL10 Ab might hinder the movement of
these CXCR3+ T cells that would otherwise migrate to the
Change in NK and NKT cells during acute cystitisFigur 5
Change in NK and NKT cells during acute cystitis. Control or anti-mouse CXCL10 Ab solutions were administered 2 
days prior to CYP treatment and every 2 days thereafter. Five days after CYP administration, lymphocytes from the spleen, 
iliac lymph nodes, and urinary bladder were isolated, stained for DX5 and CD3 expression and analyzed by flow cytometry. 
Density blots show cell distribution and indicate the percentage of DX5+ CD3- (NK) and DX5+ CD3+ (NKT) cells, respectively, 
present in leukocytes isolated from the spleen, iliac lymph node, and urinary bladder.Page 10 of 14
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CYP-induced cystitis. To explain, CYP is an "alkylating
agent" that binds DNA and disrupts cell division. Rapidly
dividing cells are especially sensitive to CYP. The mecha-
nism by which CYP modulates inflammation might be
due to the cytotoxic effect of CYP on proliferating CD25+
T cells (e.g., Treg cells). Indeed, CYP has been shown to
selectively target Treg cells [45] and lead to their reduction
in number [46]; CD4+ CD25+ T cells isolated from CYP-
treated mice display reduced suppressive activity in vitro
and increased expression of apoptotic markers. A large
body of evidence describes the mechanisms of immune
response augmentation by CYP, which include the hom-
ing and homeostatic proliferation by the creation of
space, the skewing of Th2/Th1 responses due to the
cytokine storm during the recovery phase, and the
removal or inhibition of Treg cells [47,48]. In this regard,
because of the ability of CYP to dysregulate the immune
system, it has been used to induce as well as treat immune
disorders. For example, CYP has been shown to increase
the number of Th2 cells in a model of multiple sclerosis
[49]. In contrast, CYP is used to induce type1 diabetes via
the promotion of autoimmune Th1 cells and presumably
suppression of Treg cells [50,51].
It is important to mention that acrolein, the highly reac-
tive aldehyde derived from the metabolism of CYP, is
responsible for the cystitis associated with CYP adminis-
tration [13]. Acrolein treatment causes loss of urothelium,
which is followed by leukocyte infiltration to the bladder.
Additional studies will be required to determine the exact
mechanism(s) leading to CYP- and/or acrolein-induced
cystitis in mice; however, the current study provides some
explanations for some insight into the molecular and cel-
lular mechanisms responsible for these changes and the
role of CXCL10 in CYP-induced cystitis. It has been
reported that CXCL10 triggers lymphocyte adhesion to
immobilized integrin ligands [52] and enhances colitis
through a massive infiltration of CD4+ T cells, which pro-
duce Th1 cytokines [53,54]. Environmental (e.g., acro-
lein) or pathogenic (e.g., Escherichia coli) insults induce
epithelial cells to increase their expression of CXCL10
[55], suggesting the mucosa participates in modulating T
cell-mediated inflammation via CXCR3-CXCR3 ligand
interactions.
The role of CXCL10 has been contributed to be an impor-
tant hallmark of in the of inflammatory bowel disease
(IBD) pathophysiology [39-42]. Blockade of CXCL10
ameliorated murine AIDS and acute colitis by inhibiting
cell trafficking as well as inhibiting cell proliferation while
supporting crypt epithelial cell survival [56,57]. Indeed,
CXCL10 inhibition might prove useful in other diseases.
For example, lichen sclerosus et atrophicus or white-spot dis-
ease is a chronic inflammatory skin disease where CXCR3+
cytotoxic T cells are involved in its pathogenesis [58].
These cells also contain CXCL10 in their granules to per-
petuate this disease once released. Similar observations
have been made in oral lichen planus [59].
TNF-α is a potent inducer of CXCL10 expression by
endothelial cells [60]; this inflammatory cytokine was
negatively modulated by CXCL10 blockade during CYP-
induced cystitis. The significant role of TNF-α in CYP-
induced cystitis has been reported in the past [61] and
high levels of TNF-α have been observed in the urine of IC
patients [62,63]. The described study shows that anti-
CXCL10 Ab therapy reduces TNF-α expression that corre-
lates with decreased cystitis severity. Thus, the decline in
inflammatory cytokines levels might be a reflection of
reduced inflammatory state and Th1 cell-mediated
responses afforded by CXCL10 blockade.
Mast cells are normally distributed throughout the
mucosal surface and connective tissues and have the
capacity to release or synthesize numerous inflammatory
mediators including histamine, TNF-α, and prostagland-
ins [64]. Mast cells have been implicated in a subset of IC
cases [65] and involved in ulcerative and non-ulcerative
IC [66,67]. In the present study, we noticed significant
increases in mast cell numbers in the spleen, iliac lymph
nodes, and urinary bladder after CYP induction and these
increases were abrogated by anti-CXCL10 Ab treatment.
Taken together, the present study presents a scenario
where CYP induction leads to increased numbers of both
systemic and mucosal mast cells, partially through
CXCL10-CXCR3 interactions.
While NK cell subsets have not been demonstrated to play
a profound role in IC or in CYP-induced cystitis, this study
shows that NK and NKT cells were associated with cystitis
in mice following CYP challenge, which was partially
resolved by CXCL10 blockade. NK and NKT cells express
CXCR3 and have been shown to be involved in the differ-
entiation of naïve CD4+ T cells to Th1 cells [68]. Impor-
tantly, the regulatory role of these cells may be crucial for
controlling the extent of Th1 cells activation and progres-
sion during CYP-induced cystitis. Additional studies will
be required to dissect the mechanisms of NK cell-medi-
ated cystitis.
The ratio of inflammatory Th1 to Treg cells increases dur-
ing IC [69]. Importantly, CXCR3-expressing T cells have
been shown to predominantly produce Th1 cytokines and
selectively mobilize Th1 and inflammatory lymphocytes
[70]. In the present study, we observed a significant
increase in the number of CD4+ T cells at the site of uri-
nary bladder inflammation in CYP-induced, control Ab-
treated mice than compared to similar mice treated with
anti-CXCL10 Ab. Furthermore, we observed a significantPage 11 of 14
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nary bladder lymphocytes from mice challenged with CYP
and treated with anti-CXCL10 Ab, than compared to con-
trol Ab-treated mice. CXCL10 blockade reduced the
number of CD4+ T cells at this effector site, most likely by
inhibiting chemotaxis and activation via CXCR3 interac-
tions. When considered together, the results of the present
study suggest that CYP-induced cystitis is partially Th1-
cell- and CXCR3 ligand-mediated.
Conclusion
In this mouse model, IFN-γ transcripts were not signifi-
cantly expressed by the iliac lymphocytes during CYP-
induced cystitis but were expressed by leukocytes from the
spleen and urinary bladder. The expression of CXCL9,
CXCL10, and CXCL11 can be induced by IFN-γ [71].
Hence, the current study suggests CXCL10 is partially
responsible for changes in the distribution of CXCR3+ Th1
cells, mast cells, and NKT cells from the spleen and iliac
lymph nodes to the urinary bladder after CYP treatment,
which corresponded with cystitis. Flow cytometry analysis
showed the percentage of CD4+ T cells, and NK cells was
dramatically lower in the iliac lymph nodes of CYP-
treated mice than in the iliac lymph nodes of CYP-
induced and anti-CXCL10 Ab-treated mice. In contrast,
the number of CD4+ T cells, mast cells, and NKT cells were
dramatically changed in the urinary bladders of CYP-
treated mice than compared to the number of similar cells
isolated from urinary bladders. The present study suggests
a role for CXCL10 as a mediator of leukocyte infiltration
to the urinary bladder (effector site) from the iliac and
peripheral lymphoid tissues (inductive sites) during cysti-
tis. While anti-CXCL10 Ab therapy has not been used to
treat IC, this approach (i.e., MDX-1100) has been proven
to be safe and well tolerated in the treatment of IBD, clear-
ing Phase I testing with no serious side effects [72,73].
Considered together, the CXCR3-CXCL10 axis may repre-
sent a new target for the treatment of cystitis.
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